Atezolizumab plus bevacizumab as first-line systemic therapy for hepatocellular carcinoma: a multi-institutional cohort study.

ABSTRACT:

Background

Atezolizumab plus bevacizumab is the standard of care for advanced hepatocellular carcinoma (HCC) in the first-line setting, although was only evaluated in patients with Child-Pugh (CP) A liver function in the IMbrave150 trial. We sought to determine the outcomes of these patients based on CP score and ALBI grade in the US population.

Methods

This multicenter cohort study included patients with HCC who received atezolizumab with bevacizumab as first-line systemic therapy between March 2018 and November 2023. Overall survival (OS) was determined using the Kaplan-Meier method and multivariate analyses were performed using Cox proportional hazard regression method.

Results

Among 322 patients, 226, 86, and 10 patients had CP-A, CP-B, and CP-C liver function, re

SUBMITTER: Storandt MH 

PROVIDER: S-EPMC11546648 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature